Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPHASIS: erlotinib versus docetaxel in previously treated advanced squamous NSCLC stratified by VeriStrat
NL-OMON38457Phase 3Active, not recruiting
- Sponsor
- European Thoracic Oncology Platform
- Start
- May 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing Erlotinib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Started May 2013; status: active, not recruiting.
02
Drugs
erlotinibdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON38457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38457.